21.93
0.23 (1.06%)
| Previous Close | 21.70 |
| Open | 21.74 |
| Volume | 6,823,612 |
| Avg. Volume (3M) | 7,982,650 |
| Market Cap | 15,252,130,816 |
| Price / Sales | 788.72 |
| Price / Book | 3.66 |
| 52 Weeks Range | |
| Earnings Date | 9 Feb 2026 |
| Operating Margin (TTM) | -4,823.84% |
| Diluted EPS (TTM) | -0.750 |
| Quarterly Revenue Growth (YOY) | -16.10% |
| Quarterly Earnings Growth (YOY) | -96.70% |
| Total Debt/Equity (MRQ) | 1.93% |
| Current Ratio (MRQ) | 33.47 |
| Operating Cash Flow (TTM) | -839.45 M |
| Levered Free Cash Flow (TTM) | -375.20 M |
| Return on Assets (TTM) | -10.73% |
| Return on Equity (TTM) | -12.54% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bullish | Mixed |
| Biotechnology (Global) | Bullish | Mixed | |
| Stock | Roivant Sciences Ltd. | Bullish | Bullish |
AIStockmoo Score
| Analyst Consensus | 4.0 |
| Insider Activity | -1.5 |
| Price Volatility | -0.5 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | 2.0 |
| Average | 1.30 |
|
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Mid Growth |
| % Held by Insiders | 30.31% |
| % Held by Institutions | 83.49% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 33.00 (Goldman Sachs, 50.48%) | Buy |
| Median | 29.00 (32.24%) | |
| Low | 26.00 (HC Wainwright & Co., 18.56%) | Buy |
| 26.00 (Citigroup, 18.56%) | Buy | |
| Average | 29.25 (33.38%) | |
| Total | 4 Buy | |
| Avg. Price @ Call | 21.70 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Goldman Sachs | 15 Dec 2025 | 33.00 (50.48%) | Buy | 21.90 |
| Leerink Partners | 15 Dec 2025 | 32.00 (45.92%) | Buy | 21.90 |
| HC Wainwright & Co. | 12 Dec 2025 | 26.00 (18.56%) | Buy | 22.10 |
| Citigroup | 11 Nov 2025 | 26.00 (18.56%) | Buy | 20.90 |
| 29 Oct 2025 | 25.00 (14.00%) | Buy | 18.76 |
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| VENKER ERIC | - | 22.16 | -200,000 | -4,432,000 |
| Aggregate Net Quantity | -200,000 | |||
| Aggregate Net Value ($) | -4,432,000 | |||
| Aggregate Avg. Buy ($) | - | |||
| Aggregate Avg. Sell ($) | 22.16 | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| VENKER ERIC | Officer | 12 Jan 2026 | Sell (-) | 200,000 | 22.16 | 4,432,000 |
| VENKER ERIC | Officer | 12 Jan 2026 | Option execute | 200,000 | - | - |
| Date | Type | Details |
|---|---|---|
| 11 Dec 2025 | Announcement | Roivant Highlights Continued Pipeline Progress and Outlook for Company’s Next Phase of Growth at 2025 Investor Day |
| 10 Nov 2025 | Announcement | Roivant Reports Financial Results for the Second Quarter Ended September 30, 2025, and Provides Business Update |
| 27 Oct 2025 | Announcement | Roivant to Report Financial Results for the Second Quarter Ended September 30, 2025, and Provide Business Update on Monday, November 10, 2025 |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |